UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 103 filers reported holding UROGEN PHARMA LTD in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $28,000 | – | 3,047 | +6383.0% | 0.00% | – |
Q4 2021 | $0 | -100.0% | 47 | 0.0% | 0.00% | – |
Q3 2021 | $1,000 | 0.0% | 47 | 0.0% | 0.00% | – |
Q2 2021 | $1,000 | -97.5% | 47 | -97.7% | 0.00% | -100.0% |
Q1 2021 | $40,000 | +100.0% | 2,047 | +85.6% | 0.00% | +100.0% |
Q4 2020 | $20,000 | -59.2% | 1,103 | -56.7% | 0.00% | -66.7% |
Q3 2020 | $49,000 | +81.5% | 2,547 | +143.3% | 0.00% | +50.0% |
Q2 2020 | $27,000 | -70.0% | 1,047 | -61.2% | 0.00% | -71.4% |
Q4 2019 | $90,000 | +150.0% | 2,700 | +80.0% | 0.01% | +133.3% |
Q3 2019 | $36,000 | -2.7% | 1,500 | +50.0% | 0.00% | -25.0% |
Q1 2019 | $37,000 | -14.0% | 1,000 | 0.0% | 0.00% | -33.3% |
Q4 2018 | $43,000 | +79.2% | 1,000 | +100.0% | 0.01% | +100.0% |
Q3 2018 | $24,000 | -75.8% | 500 | -75.0% | 0.00% | -78.6% |
Q2 2018 | $99,000 | +120.0% | 2,000 | +122.2% | 0.01% | +100.0% |
Q1 2018 | $45,000 | +50.0% | 900 | +12.5% | 0.01% | +40.0% |
Q4 2017 | $30,000 | -14.3% | 800 | 0.0% | 0.01% | -16.7% |
Q3 2017 | $35,000 | – | 800 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |